

FOR IMMEDIATE RELEASE

MEDIA RELEASE

**PHARMANIAGA FIRST TO COMPLETE GOVERNMENT'S
COVID-19 VACCINE REQUIREMENT AND SINOVAC IS
STILL AN APPROVED VACCINE FOR THE NATION**

Two million doses of order by the Ministry of Health in the pipeline

SHAH ALAM, 16 July, 2021 – Pharmaniaga Berhad (Pharmaniaga) refers to the published news reports yesterday that we found to have confusing statements and headlines on the discontinuation of Sinovac COVID-19 vaccine supply for National Immunisation COVID-19 Programme (NIP).

The Group has contacted the relevant parties and found that the statements and headlines of the news reports are misleading and untrue. Here are the actual facts on the reported issue.

Pharmaniaga's contractual obligation with the Federal Government is to supply 12 million doses of the Sinovac COVID-19 Fill & Finish vaccines by its high-tech plant Pharmaniaga LifeScience Sdn Bhd (PLS). The contract obliges Pharmaniaga to supply the vaccines within 7 months, between May and November 2021.

Due to the surge in the number of COVID-19 cases from March 2021, Pharmaniaga has taken proactive steps to meet the needs of the country by expediting the supply of Sinovac COVID-19 vaccines by importing finished vaccines from Sinovac to be distributed in parallel with the distribution of Fill & Finish vaccines by PLS.

With these efforts, Pharmaniaga has managed to supply a total of 12 million doses with the last batch of doses will be delivered on 21 July 2021, 4.5 months ahead of the initial contract schedule.

The supply of 12 million doses of Sinovac COVID-19 vaccines involved 6 million doses for the first injection and 6 million doses for the second injection. Since the number of first dose injections in all states is close to 6 million recipients, the Ministry of Health has instructed ceasing of first dose administration and to continue with second dose administration. This is to avoid insufficient number of vaccines for second dose if more than 6 million recipients are administered with first dose.

Pharmaniaga would like to thank the Federal Government for its trust and we are proud to be the first company to have successfully delivered all the contractual supply of vaccines to the Federal Government far ahead of the contract schedule in order to help protecting the rakyat from the COVID-19 virus.

FOR IMMEDIATE RELEASE

MEDIA RELEASE

Pharmaniaga is also ready to provide additional supplies if the Federal Government intends to continue the usage of Sinovac COVID-19 vaccines in NIP. The Group has made an offer of additional supply of 2 million doses to the Federal Government and is waiting for an official decision on it.

Meanwhile, Pharmaniaga will continue to embark on its initiative to supply Sinovac COVID-19 vaccines to state governments, government agencies and private sectors. These agencies have been waiting to procure Sinovac COVID-19 vaccines, whilst helping to speed up the completion of the NIP.

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad group of companies, and together with Lembaga Tabung Angkatan Tentera, are the major shareholders of the Company.

-End-

About Pharmaniaga Berhad

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy.

With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena.

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial conditions, results of operations and business of the Group and certain plans and objectives of Pharmaniaga Berhad with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad.

For media enquiries, please contact Dato' Zuhri Iskandar Kamarzaman, Head of Corporate Communications Department, Pharmaniaga Berhad at 03 3342 999 ext. 434 or by email zuhri@pharmaniaga.com